Geulah Livshits
Stock Analyst at Chardan Capital
(4.14)
# 493
Out of 5,182 analysts
262
Total ratings
44.27%
Success rate
15.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $210 → $240 | $123.17 | +94.85% | 9 | Mar 31, 2026 | |
| SNTI Senti Biosciences | Maintains: Buy | $13 → $11 | $0.85 | +1,190.93% | 12 | Mar 30, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.60 | +205.56% | 23 | Mar 27, 2026 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $8.02 | +87.03% | 11 | Mar 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.55 | +163.74% | 18 | Mar 19, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $10.10 | +157.43% | 15 | Mar 19, 2026 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $8 | $0.73 | +1,003.14% | 15 | Mar 12, 2026 | |
| EDIT Editas Medicine | Maintains: Buy | $3.5 | $2.76 | +26.81% | 11 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $26 → $27 | $13.87 | +94.66% | 19 | Mar 2, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $220 → $323 | $264.22 | +22.25% | 15 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $76 | $51.76 | +46.83% | 17 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 | $6.44 | +163.98% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $10.53 | +137.42% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.50 | +263.64% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $9.29 | +126.05% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.54 | +154.24% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $3.47 | +389.91% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.39 | +691.37% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.29 | +162.01% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $9.39 | +336.63% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.09 | +288.35% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $52.10 | +299.23% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.99 | +1,516.16% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.67 | +938.06% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.92 | +2.04% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $21.70 | -17.05% | 1 | Oct 27, 2020 |
Palvella Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $210 → $240
Current: $123.17
Upside: +94.85%
Senti Biosciences
Mar 30, 2026
Maintains: Buy
Price Target: $13 → $11
Current: $0.85
Upside: +1,190.93%
Rocket Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $11
Current: $3.60
Upside: +205.56%
Solid Biosciences
Mar 20, 2026
Maintains: Buy
Price Target: $15
Current: $8.02
Upside: +87.03%
Taysha Gene Therapies
Mar 19, 2026
Maintains: Buy
Price Target: $12
Current: $4.55
Upside: +163.74%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $26
Current: $10.10
Upside: +157.43%
Tenaya Therapeutics
Mar 12, 2026
Maintains: Buy
Price Target: $8
Current: $0.73
Upside: +1,003.14%
Editas Medicine
Mar 9, 2026
Maintains: Buy
Price Target: $3.5
Current: $2.76
Upside: +26.81%
Intellia Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $26 → $27
Current: $13.87
Upside: +94.66%
Krystal Biotech
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $264.22
Upside: +22.25%
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $51.76
Upside: +46.83%
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $6.44
Upside: +163.98%
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $10.53
Upside: +137.42%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.50
Upside: +263.64%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $9.29
Upside: +126.05%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.54
Upside: +154.24%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $3.47
Upside: +389.91%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.39
Upside: +691.37%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.29
Upside: +162.01%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $9.39
Upside: +336.63%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $3.09
Upside: +288.35%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $52.10
Upside: +299.23%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.99
Upside: +1,516.16%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.67
Upside: +938.06%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.92
Upside: +2.04%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $21.70
Upside: -17.05%